PTGS2 and metabolic disease: Specific future focus should be maintained not only on suppression of TNF-α signaling as a critical target in the onset of insulin resistance, but also on the putative protective roles of the COX-2-mediated or IL-17A-mediated pathways in metabolic disorders.